MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
26.77
-1.21
-4.32%
Opening 12:05 02/27 EST
OPEN
26.86
PREV CLOSE
27.98
HIGH
27.19
LOW
26.01
VOLUME
174.45K
TURNOVER
--
52 WEEK HIGH
31.18
52 WEEK LOW
1.920
MARKET CAP
1.63B
P/E (TTM)
-6.4993
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KOD last week (0216-0220)?
Weekly Report · 4d ago
First Week of April 17th Options Trading For Kodiak Sciences (KOD)
NASDAQ · 02/20 17:04
Analysts Are Bullish on Top Healthcare Stocks: CervoMed (CRVO), Kodiak Sciences (KOD)
TipRanks · 02/20 15:30
Weekly Report: what happened at KOD last week (0209-0213)?
Weekly Report · 02/16 10:07
Kodiak Sciences Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 02/10 12:47
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $38 Price Target
Benzinga · 02/10 12:37
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Protara Therapeutics (TARA) and Kodiak Sciences (KOD)
TipRanks · 02/10 11:30
Analysts Offer Insights on Healthcare Companies: Kodiak Sciences (KOD) and Entera Bio (ENTX)
TipRanks · 02/09 11:30
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.